NCT06671314View on ClinicalTrials.gov

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

CompletedOBSERVATIONAL
Enrollment

42,494

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY